Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-08 16:06:39 - browse：1245

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Opioid cravings were reduced by anti

focus

WSS

Reporting on presidential health from Reagan to Trump and Biden

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

After affirmative action ruling, medical educators look to 'holistic review'

STAT Readout Newsletter: Biotech news today

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Summit: The economic case for universal basic health care

BioMarin wins approval for gene therapy to treat hemophilia A

Smaller biotechs seek to piggyback on weight loss drug boom

As demand for Covid shots wanes, Moderna seeks its next success

WATCH: Why do our ears pop?

entertainment

Smaller biotechs seek to piggyback on weight loss drug boom

STAT Summit: The economic case for universal basic health care

STAT Summit: The economic case for universal basic health care

Opioid cravings were reduced by anti

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Medicare Advantage enrollment hits roughly 33.4 million

focus

entertainment

focus

Wikipedia